Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Columbia Striant approved

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Columbia Labs will launch its novel testosterone replacement patch Striant (testosterone buccal system) third quarter 2003, the firm said. FDA cleared the product June 19 for treatment of conditions associated with a deficiency or absence of endogenous testosterone, including hypogonadism. The firm will "immediately expand its existing sales force to 135 professionals who will add endocrinologists, urologists and a select group of primary care physicians to their current target list of OB/GYNs." Distribution, managed care and thought leader programs are underwa
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel